| | 
Part, Chapter, Paragraph
1 -, 1 | Narrowing the Health gap”;~b) in 1996, “The State of
2 II, 4. 3 | Sustainable Progress and Policies. B. Marin and A. Zaidi. Aldershot -
3 II, 5. 1. 1 | average (2001-2003), EU27 – B) Men.~ ~ ~ ~Table 5.1.1.
4 II, 5. 1. 1 | disease, i.e., hepatitis B and C virus (HBV and HCV)
5 II, 5. 2. 6 | 1839.~Robinson JG, Smith B, Maheshwari N, Schrott H (
6 II, 5. 2. 7 | 1231–48.~Sarti C, Stegmayr B, Tolonen H, MAhonen M, Tuomilehto
7 II, 5. 2. 7 | Q 41(3-4):155–178.~Unal B, Critchley JA, Fidan D,
8 II, 5. 3. 5 | standard) by sex in 2006 B) Women~ ~Figure 5.3.2a.
9 II, 5. 3. 5 | European standard) by sex B) Women~ ~ ~Figure 5.3.3a.
10 II, 5. 3. 5 | standard) by sex in 2006 B) Women~ ~Figure 5.3.4a.
11 II, 5. 3. 5 | European standard) by sex B) Women~ ~Stomach Cancer (
12 II, 5. 3. 5 | standard) by sex in 2006 B) Women~ ~Figure 5.3.6a.
13 II, 5. 3. 5 | European standard) by sex B) Women~ ~Figure 5.3.7a.
14 II, 5. 3. 5 | standard) by sex in 2006 B) Women~ ~Figure 5.3.8a.
15 II, 5. 3. 5 | European standard) by sex B) Women~ ~Colorectal Cancer (
16 II, 5. 3. 5 | standard) by sex in 2006 B) Women~ ~Figure 5.3.10a.
17 II, 5. 3. 5 | European standard) by sex B) Women~ ~Figure 5.3.11a.
18 II, 5. 3. 5 | standard) by sex in 2006 B) Women~ ~Figure 5.3.12a.
19 II, 5. 3. 5 | European standard) by sex B) Women~ ~ ~Lung Cancer (
20 II, 5. 3. 5 | standard) by sex in 2006 B) Women~ ~Figure 5.3.14a.
21 II, 5. 3. 5 | European standard) by sex B) Women~ ~Figure 5.3.15a.
22 II, 5. 3. 5 | standard) by sex in 2006 B) Women~ ~Figure 5.3.16a.
23 II, 5. 3. 5 | European standard) by sex B) Women~ ~Female Breast Cancer (
24 II, 5. 3. 6 | up to 31st December 1999 B) Women~ ~Countries fell
25 II, 5. 3. 6 | up to 31st December 1999 B) Women~ ~5-year colorectal
26 II, 5. 3. 6 | up to 31st December 1999 B) Women~ ~Survival for lung
27 II, 5. 3. 6 | up to 31st December 1999 B) Women~ ~The prognosis for
28 II, 5. 3. 9 | Inst 94:606-616.~ ~Jonsson B, Wilking N (2007): Summary.
29 II, 5. 4. 8 | Pages S215 – S219~Carstensen B, Kristensen JK, Ottosen
30 II, 5. 4. 8 | J, Nilsson PM, Eliasson B; Steering Committee of the
31 II, 5. 4. 8 | Pract 61(4):680-3~Jönsson B (2002), CODE-2 Advisory
32 II, 5. 5. 1 | Longevity Center.~ ~Kennelly B (2007). The economic cost
33 II, 5. 5. 2 | Eastern Europe (Regions B and C)23. ~ ~Apart from
34 II, 5. 5. 2(23)| The EURO B category included countries
35 II, 5. 5. 2 | December 2007)~ ~Cooper B (2002): Thinking preventively
36 II, 5. 5. 3 | Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J (
37 II, 5. 5. 3 | 502-8.~Buizza C, Schulze B, Bertocchi E, Rossi G, Ghilardi
38 II, 5. 5. 3 | D, Bingefors K, Widerlöv B (2007): Mortality among
39 II, 5. 5. 3 | Saxena S, Levav I, Saraceno B (2004): The treatment gap
40 II, 5. 5. 3 | M, Wahlbeck K), Section B, p. 257-333, 2007.~htt df~
41 II, 5. 5. 3 | Harris EC, Barraclough B (1997): Suicide as an outcome
42 II, 5. 5. 3 | structure, ethnic origin; (b) the capability to detect
43 II, 5. 5. 3 | of disease progression, (b) progressive-relapsing MS (
44 II, 5. 5. 3 | 457.~Celius EG, Vandvik B (2001): Multiple sclerosis
45 II, 5. 5. 3 | 48: 91–94.~Koncan-Vracko B (1994): Epidemiological
46 II, 5. 5. 3 | u T, eaManceau E, Lucas B, Lemesle M, Urbinelli R,
47 II, 5. 5. 3 | Med 343;938-952.~Peterlin B, Ristic S, Sepcic J, et
48 II, 5. 5. 3 | 227–231.~Poser S, Stickel B, Krtsch U, Burckhardt D,
49 II, 5. 5. 3 | U, Burckhardt D, Nordman B (1989): Increasing incidence
50 II, 5. 5. 3 | continuously ageing population, and b) will be increasingly dominated
51 II, 5. 5. 3 | Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J (
52 II, 5. 5. 3 | Koehne-Volland R, Szucs T, Rathay B, Scholz E, Oertel WH (1998):
53 II, 5. 5. 3 | M, Machat O, Bornschein B, von Campenhausen S, Berger
54 II, 5. 5. 3 | Sutcliffe RL, Prior R, Mawby B, McQuillan WJ (1985): Parkinson’
55 II, 5. 5. 3 | Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio
56 II, 5. 6. 2 | Health)~· Woolf AD, Pfleger B Burden of Osteoporosis and
57 II, 5. 6. 3 | Netherlands~ ~Figure 5.6.2.b Prevalence of self reported
58 II, 5. 6. 3 | of radiographic OA by age B) Women~ ~Determinants, risk
59 II, 5. 6. 6 | Petersson IF, Svensson B, Jacobsson LT (2001): Chronic
60 II, 5. 6. 6 | Lancet 353:878-882~Combe B, Landewe R, Lukas C, Bolosiu
61 II, 5. 6. 6 | Gabriel KR, Lequesne M, Amor B (1992): Longitudinal radiologic
62 II, 5. 6. 6 | Jacobson L. and Lindgren B (1996): Vad kostar sjukdomarna? (
63 II, 5. 6. 6 | Petterson C, De Laet C, Jonsson B (2004): Mortality after
64 II, 5. 6. 6 | Oden A, De Laet C, Jonsson B, Dawson A (2002): Ten-year
65 II, 5. 6. 6 | Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000):
66 II, 5. 6. 6 | Available at URL: htt ~ ~Natvig B, Nessiøy I, Bruusgaard D,
67 II, 5. 6. 6 | 1141~Ollier WE, Harrison B, Symmons D (2001) What is
68 II, 5. 6. 6 | 197~Symmons D, Harrison B (2000): Early inflammatory
69 II, 5. 6. 6 | Mathers C, and Pfleger B (2003): Global Burden of
70 II, 5. 6. 6 | 89-95~Woolf AD, Pfleger B (2005): Burden of osteoporosis
71 II, 5. 6. 6 | 347~Woolf AD and Pfleger B (2003): Burden of Major
72 II, 5. 7. 3 | Germany (Tables 5.7.6 A and B). It increased with age
73 II, 5. 7. 7 | Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al, Kidney
74 II, 5. 7. 7 | May;15(5):1300-6.~Stengel B, Billon S, van Dijk PC,
75 II, 5. 7. 7 | DJ, de LS, Van VJ, Klebe B, Middleton R, et al (2007):
76 II, 5. 7. 7 | Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok
77 II, 5. 8. 7 | Flodin R, and Järvholm B (2004): Increased mortality
78 II, 5. 8. 7 | Neukirch F, Kunzli N, Leynaert B, Janson C, Gislason T, Vermeire
79 II, 5. 8. 7 | 59: 120–125.~ ~Detournay B, Pribil C, Fournier M, Housset
80 II, 5. 8. 7 | Pribil C, Fournier M, Housset B, Huchon G, Huas D, Godard
81 II, 5. 8. 7 | Ericsson A, Jonsson E, Lundback B (2002): Costs of COPD in
82 II, 5. 8. 7 | E, Larsson LG, Lundback B. (2006): Prevalence and
83 II, 5. 8. 7 | R, Larsson LG, Lundback B (2005): Ten-year cumulative
84 II, 5. 8. 7 | Lindberg A, Eriksson B, Larsson LG, Ronmark E,
85 II, 5. 8. 7 | E, Sandstrom T, Lundback B (2006): Seven-year cumulative
86 II, 5. 8. 7 | 367: 1747-1757.~ ~Lundback B, Lindberg A, Lindstrom M,
87 II, 5. 8. 7 | Schirnhofer L, Lamprecht B, Vollmer WM, Allison MJ,
88 II, 5. 8. 7 | Egger P, Visick G, Thakrar B, Sykes J, Pride NB (2000):
89 II, 5. 9. 7 | Heinrich J Gehring U, , Jacob B, Richter K, Fahlbusch B,
90 II, 5. 9. 7 | B, Richter K, Fahlbusch B, Schlenvoigt G, Bischof
91 II, 5. 9. 7 | conceptual issues. In: Spilker B Editors. Quality of Life
92 II, 5. 10. 5 | Fish and products thereof (b)~- Peanuts and products
93 II, 5. 10. 5 | alcoholic beverages.~ ~(b) fish gelatine used as carrier
94 II, 5. 10. 7 | DunnGalvin A,. Hourihane JO'B, Cornelisse-Vermaat JR,
95 II, 5. 10. 7 | DunnGalvin A, Hourihane JO'B, Frewer L, Knibb RC, Oude
96 II, 5. 11. 3 | including mild cases)~Meding B, et al~ ~Swedish school
97 II, 5. 11. 3 | 13 to 20% in the 1980s (B Larsson-Stymne and L Widström,
98 II, 5. 11. 3 | contact allergy to cobalt (B Larsson-Stymne and L Widström,
99 II, 5. 11. 3 | with the law standards (B Bocca et al, 2007). Similarly,
100 II, 5. 11. 3 | Medicine 1999;14(6):379–385.~B Larsson-Stymne, L Widstrom,
101 II, 5. 11. 7 | 30:35-9.~ ~Larsson-Stymne B, Widstrom L (1985): Ear
102 II, 5. 11. 7 | eczema eds T Ruzicka, J Ring, B Pryzbilla). London: Springer-Verlag,
103 II, 5. 11. 7 | K, Krakauer R, Wanscher B (1980): Prevalence of skin
104 II, 5. 12.Acr | European Union~HBV~Hepatitis B virus~HCV~Hepatitis C virus~
105 II, 5. 12. 1 | disease, i.e., hepatitis B and C virus (HBV and HCV)
106 II, 5. 12. 3 | in Figures 5.12.1 (A and B) and 5.12.2 (A and B).~ ~ ~ ~
107 II, 5. 12. 3 | and B) and 5.12.2 (A and B).~ ~ ~ ~Table 5.12.1 gives
108 II, 5. 12. 4 | disease, i.e., hepatitis B and C virus (HBV and HCV)
109 II, 5. 12. 7 | Mele A, Ortolani G, Adamo B, Rapicetta M, Forte P,~Pisani
110 II, 5. 12. 7 | Pisani A, Soldo L, Sarrecchia B, et al (1989): Decline in
111 II, 5. 12. 7 | exposure to hepatitis A and B infections in children in
112 II, 5. 12. 7 | Mantion G, Messner M, Launois B, Samuel D, Cherqui D, et
113 II, 5. 12. 7 | Margolis HS (1990): Hepatitis B epidemiology and prevention.
114 II, 5. 12. 7 | changing pattern of hepatitis B virus infection over the
115 II, 5. 14. 2 | years of age surveyed.~ ~b. Dental Contact within the
116 II, 5. 15. 6 | 2007)~Wastfelt M, Fadeel B, Henter JI. A journey of
117 II, 6.Acr | Response System~HBV~Hepatitis B Virus~HCAI~Health Care Associated
118 II, 6.Acr | Haemophilus Influenzae type B~HPV~Human Papilloma Virus~
119 II, 6. 3. 3 | section addresses hepatitis B and C.~ ~Hepatitis B~ ~Hepatitis
120 II, 6. 3. 3 | hepatitis B and C.~ ~Hepatitis B~ ~Hepatitis B is an infection
121 II, 6. 3. 3 | Hepatitis B~ ~Hepatitis B is an infection of the liver
122 II, 6. 3. 3 | liver caused by hepatitis B virus (HBV). HBV can result
123 II, 6. 3. 3 | transmission. Hepatitis B has to be considered increasingly
124 II, 6. 3. 3 | 180 000 cases of Hepatitis B were reported in Europe
125 II, 6. 3. 3 | have included hepatitis B vaccine in their national
126 II, 6. 3. 3 | incidence of acute hepatitis B infection had been declining
127 II, 6. 3. 4 | by influenza virus A and B. Each year there are epidemics
128 II, 6. 3. 4 | for the season. Influenza B viruses were co-circulating
129 II, 6. 3. 4 | countries the proportion of B viruses was higher than
130 II, 6. 3. 5 | Haemophilus influenzae type b in the countries that have
131 II, 6. 3. 5 | is caused by serogroups B and C. Since 1999, several
132 II, 6. 3. 5 | vaccine against serogroup B disease.~ ~Since 1999, countries
133 II, 6. 3. 5 | Haemophilus influenzae type b~ ~Haemophilus influenzae
134 II, 6. 3. 5 | Haemophilus influenzae type b (Hib) is a respiratory tract
135 II, 6. 3. 7 | military and laboratory staff. B. anthracis has been recorded
136 II, 6. 4. 5 | occurrence of resistant strains; b) put in place and improve
137 II, 6. 4. 5 | authorization to market antibiotics; b) support, at Community level,
138 II, 6. 4. 5 | treatments and vaccines; b) support the development
139 II, 7. 3. 5 | European Union (Figure 7.15.b. Suicide and intentional
140 II, 7. 3. 5 | Figure 7.16).~ ~Figure 7.15.b. Suicide and intentional
141 II, 7. 4. 1 | injury deaths (Figure 7.19.B).~ ~Figure 7.19.b. Fatal
142 II, 7. 4. 1 | Figure 7.19.B).~ ~Figure 7.19.b. Fatal injuries by causes
143 II, 7. 7 | on 15 April 2008].~ ~Guo B, Harstall C (2004). For
144 II, 8. 2. 1 | Valk, H., Buono, S., Azema, B., Aussilloux, C., Määttä,
145 II, 8. 2. 2 | Organization 86:63–70.~Thylefors B, Négrel A-D, Pararajasegaram
146 II, 8. 2. 3 | 2003;42:18-28~ ~Karlsmose B, Lauritzen T, Parving A (
147 II, 9. 1. 1 | 82(2):257-61.~ ~Blondel B, Macfarlane A, Gissler M,
148 II, 9. 1. 1 | Draper ES, Manktelow B, Field DJ, James D (1999):
149 II, 9. 1. 1 | 452-60.~ ~Gould JB, Davey B, Stafford RS (1989): Socioeconomic
150 II, 9. 1. 1 | 2000;95(2):215-21.~ ~Kahn B, Lumey LH, Zybert PA, Lorenz
151 II, 9. 1. 1 | 92.~Kaminski M, Blondel B, Saurel-Cubizolles M-J (
152 II, 9. 1. 1 | Platt RW, Yang H, Haglund B, Cnattingius S, Bergsjo
153 II, 9. 1. 1 | Epidemiol 16(1):16-22.~ ~Langer B, Caneva MP, Schlaeder G (
154 II, 9. 1. 1 | J, Kesmodel U, Jacobsson B, Rasmussen S, Vogel I (2006):
155 II, 9. 1. 1 | 2004;103(1):128-36.~Luke B, Brown MB (2007a). Elevated
156 II, 9. 1. 1 | 2007;22(5):1264-72.~Luke B, Brown MB (2007b). Contemporary
157 II, 9. 1. 1 | 84.~ ~Zeitlin J, Blondel B, Alexander S, Breart G (
158 II, 9. 1. 1 | Alexander S, Barros H, Blondel B, et al (2003): Selecting
159 II, 9. 1. 2 | anomaly in that country b) the level of investigation
160 II, 9. 1. 2 | the baby is not viable. ~ ~b) Hospital Episode or Discharge
161 II, 9. 1. 2 | infant death certificates b) the potential to link registry
162 II, 9. 1. 2 | special susceptibility.~ ~b) Policies aimed at ensuring “
163 II, 9. 1. 2 | Busby A, Armstrong B, Dolk H, Armstrong N, Haeusler
164 II, 9. 1. 2 | Latos-Bielenska A, Gener B, Portillo I, Addor M-C,
165 II, 9. 1. 2 | Daltveit, A, Aneren G, Ollars B, Edwards G (2005a): "Preventing
166 II, 9. 1. 2 | Abramsky L, Dolk H, Armstrong B and a EUROCAT Folic Acid
167 II, 9. 1. 2 | Candela S, Dale I, Danaché B, De Vigan C, Fevotte J,
168 II, 9. 1. 2 | Vigan C, Addor M-C, Gener B, Haeusler M, Jordan H, Tucker
169 II, 9. 1. 2 | Scott JES, Addor MC, Botting B, de Vigan C, de Walle H,
170 II, 9. 1. 2 | Nelen V, Bakker M, Gener B, Abramsky L, Addor M-C and
171 II, 9. 2. 3 | leukaemias (Figures 9.2.1a and b). Leukaemia is often successfully
172 II, 9. 2. 7 | Lerner, R.M., Orlos, J.B., Knapp, J.R. (1976): Physical
173 II, 9. 3. 1 | nature of the diseases and (b) those women with osteoporosis
174 II, 9. 3. 1 | G Klotz, T Reifenrath, B Mathers, M Engleman, U (
175 II, 9. 3. 2 | 82(2):257-61.~ ~Blondel B, Macfarlane A, Gissler M,
176 II, 9. 3. 2 | Draper ES, Manktelow B, Field DJ, James D (1999):
177 II, 9. 3. 2 | 452-60.~ ~Gould JB, Davey B, Stafford RS (1989): Socioeconomic
178 II, 9. 3. 2 | 2004;103(3):551-63.~ ~Kahn B, Lumey LH, Zybert PA, Lorenz
179 II, 9. 3. 2 | 92.~ ~Kaminski M, Blondel B, Saurel-Cubizolles M-J (
180 II, 9. 3. 2 | Platt RW, Yang H, Haglund B, Cnattingius S, Bergsjo
181 II, 9. 3. 2 | 14(3):194-210.~ ~Langer B, Caneva MP, Schlaeder G (
182 II, 9. 3. 2 | J, Kesmodel U, Jacobsson B, Rasmussen S, Vogel I (2006):
183 II, 9. 3. 2 | the United Kingdom.~ ~Luke B, Brown MB (2007a). Elevated
184 II, 9. 3. 2 | 2007;22(5):1264-72.~ ~Luke B, Brown MB (2007b). Contemporary
185 II, 9. 3. 2 | Marchand L, Pierrat V, Larroque B, et al (2007): Neonatal
186 II, 9. 3. 2 | 84.~ ~Zeitlin J, Blondel B, Alexander S, Breart G (
187 II, 9. 3. 2 | Alexander S, Barros H, Blondel B, et al (2003): Selecting
188 II, 9. 3. 3 | Bajos N, Wadsworth J, Ducot B, Johnson AM, Le Pont F,
189 II, 9. 3. 3 | Johnson AM, McManus S, Erens B (2001): Measuring sexual
190 II, 9. 3. 3 | Johnson A, Mercer C, Erens B, et al (2001): Sexual behaviour
191 II, 9. 3. 3 | 1835-42.~Kangas I, Andersen B, McGarrigle CA, Østergaard
192 II, 9. 3. 3 | Macdowall W, McManus S, Erens B, Mercer CH, Johnson AM,
193 II, 9. 4. 7 | Rathmann W, Haastert B, Icks A et al (2005) The s.
194 II, 9. 5. 3 | Kingdom (England & Wales) b ( 2000 data )~· 4.9% of
195 II, 9. 5. 3 | European Women’s Lobby, 2001~b London Metropolitan University,
196 II, 9. 5. 3 | University, 2003 ~ ~ ~ ~B. Information of domestic
197 III, 10. 1. 3 | 376-90.~Melzer K, Kayser B, Saris WHM, Pichard C (2005):
198 III, 10. 1. 3 | 91(11):1615-1621.~Rosner B (2000): Fundamentals of
199 III, 10. 2. 1 | Cerveri I, Kerhof M, Leynaert B, Luczynska C, Neukirch F,
200 III, 10. 2. 1 | References~ ~Anderson P, Baumberg B (2006): Alcohol in Europe:
201 III, 10. 2. 1 | Heather N, Saunders J, Burnand B (2007): Effectiveness of
202 III, 10. 2. 1 | School Children~HBV~Hepatitis B Virus~HCV~Hepatitis C Virus~
203 III, 10. 2. 1 | IDUs there is hepatitis B. The prevalence of markers
204 III, 10. 2. 1 | mainly HIV/Aids and hepatitis B and C) among drug users
205 III, 10. 2. 1 | van Loveren C, Fernandes B, Seppa L, Athanassouli T.
206 III, 10. 2. 1 | Norlund A, Petersson LG, Soder B. Caries preventive effect
207 III, 10. 2. 1 | al, 2006) is available.~ ~b) Health behaviour in school-aged
208 III, 10. 2. 1 | hours spent sitting).~ ~b) Comparability of data sources~
209 III, 10. 2. 1 | Exercise, 26:857-865.~ ~Popkin B M, Duffey K, Gordon-Larsen
210 III, 10. 2. 1 | listed under references.~ ~b) Food consumption and dietary
211 III, 10. 2. 1 | Dietary-history~28~Mensink G B M et.al. (2004) Food and
212 III, 10. 2. 1 | Health Nutr., 2001, 4, 5(B), p. 1183-1186~Portugal~
213 III, 10. 2. 1 | Foz-Sala M, Moreno-Esteban B, for the Grupo Colaborativo
214 III, 10. 2. 1 | Pudule I, Jēce I, Velika B, Grīnberga D, Villeruša
215 III, 10. 2. 1 | Andersson M, de Benoist B, Darnton-Hill I, Delange
216 III, 10. 2. 1 | Linseisen J, Schulz M, Hemon B, Riboli E (2002): Consumption
217 III, 10. 2. 1 | Palmqvist R, Van Guelpen B, Bingham SA, McTaggart A,
218 III, 10. 2. 1 | Klipstein-Grobusch K, San-Jose B, Welch AA, Krogh V, Luben
219 III, 10. 2. 4 | 349: 969-974.~ ~Childs B, Valle D (2000): Genetics,
220 III, 10. 2. 4 | Washington~ ~Gao J, Shan G, Sun B, Thompson PJ, Gao X (2006):
221 III, 10. 2. 4 | EA, Boffetta P, Armstrong B, Cozen W, Linet M, Bosch
222 III, 10. 2. 4 | Whitby D, Moore PS, Leaderer B, Lai A, Spink C, Davis S,
223 III, 10. 3. 1 | Tirmarche M, Caër S, Quesne B, Laurier D (2007): Lung
224 III, 10. 3. 1 | McMichael T, Smith W, Armstrong B (2006) Prüss-Üstün A, Zeeb
225 III, 10. 3. 1 | noise. Edited by: Berglund B, Lindvall T, Schwela D.~
226 III, 10. 3. 2 | A Alimonti, F Petrucci, B Bocca, P Schramel, M Zischka,
227 III, 10. 3. 2 | September 2005. htt ~ ~Vieth B, Rüdiger, R, Ostermann,
228 III, 10. 3. 2 | Rüdiger, R, Ostermann, B, Mielke, H. (2005): Rückstände
229 III, 10. 3. 3 | Haemophilus influenzae type b~vCJD~Variant Creutzfeldt-Jakob
230 III, 10. 3. 3 | by influenza virus A and B; each year there are epidemics
231 III, 10. 3. 3 | Haemophilus influenzae type b (Hib) is a respiratory tract
232 III, 10. 3. 4 | 2007a~Menne, 2005~ ~Menne B, Ebi KL (Eds.)(2006): Climate
233 III, 10. 4. 1 | between scenario A and B above). Although this means
234 III, 10. 4. 2 | additives, feed hygiene; b) animal health and welfare:
235 III, 10. 4. 2 | a) risk assessment and (b) risk communication. Its
236 III, 10. 4. 2 | requiring rapid action; (b) any recommendation or agreement
237 III, 10. 4. 2 | Escherichia coli.~ ~Other 'list B' zoonoses should be included
238 III, 10. 4. 2 | 6.4 specified in Chapter B.I of Annex III of the TSE
239 III, 10. 4. 2 | for nitrate (0-3.7 mg/kg b.w) and nitrite (0-0.07 mg/
240 III, 10. 4. 2 | and nitrite (0-0.07 mg/kg b.w) (FAO/WHO, 2003). Exposure
241 III, 10. 4. 2 | modified organisms (mainly Part B thereof);~· The placing
242 III, 10. 4. 2 | appropriate. (EFSA, 2006 b)~ ~Emerging risk~ ~With
243 III, 10. 4. 2 | appropriateness of official controls; (b) that staff carrying out
244 III, 10. 4. 2 | authorities to be engaged; (b) their powers and responsibilities;
245 III, 10. 4. 5 | Figure 10.4.5.1.1. A and B) (EEA, 2008).~ ~Figure 10.
246 III, 10. 4. 5 | water~ ~Figure 10.4.5.1.1.b. Bathing water. Compliance
247 III, 10. 4. 5 | fourth assessment” (EEA, 2007 b), chapters on Sustainable
248 III, 10. 5. 1 | capital and trust, and (b) increased levels of physical activity
249 III, 10. 5. 1 | of urban conditions and (b) for the improvement of
250 III, 10. 5. 1 | Change Biology.~Konlaan, B B. Bygren, L O. Johansson,
251 III, 10. 5. 1 | Change Biology.~Konlaan, B B. Bygren, L O. Johansson,
252 III, 10. 5. 1 | 12.~Loftness V, Hakkinen B, Adan O, Nevalainen A (2007):
253 III, 10. 5. 1 | Michaud C, Murray C, Bloom B (2001): Burden of disease
254 III, 10. 5. 1 | 2003, vol 93, p 288~Said B et al. Outbreaks of infectious
255 III, 10. 5. 3 | Andlin-Sobocki P, Jönsson B, Wittchen H-U, Olesen J (
256 III, 10. 6. 1 | 7.~ ~Ganster DC, Victor B (1998). The impact of social
257 IV, 11. 1. 3 | increasing cost sharing; b) introducing competition
258 IV, 11. 1. 6 | doctor’s discretion); and b) referrals to specialists
259 IV, 11. 5. 4 | Transmission of HIV/AIDS, hepatitis B and C, bacteria, fungi and
260 IV, 11. 5. 6 | sense and sensitization by B Bradley and S Gore, Martinus
261 IV, 11. 6. 4 | for their population; and b) adjusting the resource
262 IV, 11. 6. 4 | insured population; and b) the size of their revenue
263 IV, 11. 6. 5 | 258.~ ~Burgers JS, Fervers B et al. (2004): "International
264 IV, 11. 6. 5 | systems in Western Europe. R. B. Saltman, R. Busse and J.
265 IV, 11. 6. 5 | Equity in Health.~ ~Gibis B, Koch-Wulkan PW et al. (
266 IV, 11. 6. 5 | systems in Western Europe. R. B. Saltman, R. Busse and J.
267 IV, 11. 6. 5 | care reform in Europe. R. B. Saltman, J. Figueras and
268 IV, 11. 6. 5 | Macinko J, Starfield B et al. (2003): "The contribution
269 IV, 11. 6. 5 | Organization.~ ~McGrail K, Green B et al. (2000): "Age, costs
270 IV, 11. 6. 5 | Blackwell Publishing.~ ~Merkel B, Hübel M (1999): Public
271 IV, 11. 6. 5 | systems in Western Europe. R. B. Saltman, R. Busse and J.
272 IV, 11. 6. 5 | Policy 6: 145-50.~ ~Starfield B, Shi L et al. (2005): "The
273 IV, 11. 6. 5 | Taggiasco Nì, Sarrut B et al. (1992): "European
274 IV, 12. 1 | stringent protective measures;~(b) by way of derogation from
275 IV, 12. 5 | HLY was awarded a grade B. The two main issues were
276 IV, 12. 10 | National/Regional~ ~ ~ ~B) Actions adopted in relation
277 IV, 12. 10 | physical activity is included.~ ~B. "6 a day" consists of an
278 IV, 12. 10 | Koch-Institute (see www. ~ ~B) Actions adopted in relation
279 IV, 12. 10 | launched on June 16th 2008.~ ~ ~B) Actions adopted by Member
280 IV, 12. 10 | diseases (i.e. Hepatitis B & C, HPV, Syphilis, and
281 IV, 12. 10 | Prevention Plan 2005-2007.~ ~ ~ ~B) Actions adopted in relation
282 IV, 12. 10 | working in this area.~ ~ ~B) Actions adopted in relation
283 IV, 12. 10 | condom during the last month~B: had sex without a condom "
284 IV, 12. 10 | determinants~No indicator~ ~ ~ ~ ~B) Actions adopted in relation
285 IV, 12. 10 | determinants~ Intermediate~ ~ ~ ~ ~B) Actions adopted in relation
286 IV, 13. 4 | ESF regulation art. 3.1(b)) provides for: "specific
287 IV, 13. 9 | Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J (
|
|
| |
